Antigeno oligosacarido meningococo grupo a, Antigeno oligosacarido meningococo grupo c, Antigeno oligosacarido meningococo grupo w135, Antigeno oligosacarido meningococo grupo y

Menveo Polvo y Solucion Para Solucion Inyectable

10 µg + 5 µg + 5 µg + 5 µg polvo y solución para solución inyectableSpainAuthorisedAuthorised 28 Jul 2011

Product informationAsk Osler about it

Packs

Pack	Code	Status
MENVEO POLVO Y SOLUCION PARA SOLUCION INYECTABLE, 5 viales + 5 viales de disolvente	605166

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Antigeno oligosacarido meningococo grupo a, Antigeno oligosacarido meningococo grupo c, Antigeno oligosacarido meningococo grupo w135, Antigeno oligosacarido meningococo grupo y

Menveo Polvo y Solucion Para Solucion Inyectable

10 µg + 5 µg + 5 µg + 5 µg polvo y solución para solución inyectableSpainAuthorisedAuthorised 28 Jul 2011

Product informationAsk Osler about it

Packs

Pack	Code	Status
MENVEO POLVO Y SOLUCION PARA SOLUCION INYECTABLE, 5 viales + 5 viales de disolvente	605166

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substances: Antigeno oligosacarido meningococo grupo a, Antigeno oligosacarido meningococo grupo c, Antigeno oligosacarido meningococo grupo w135, Antigeno oligosacarido meningococo grupo y
Strength: 10 µg + 5 µg + 5 µg + 5 µg
Dosage form: polvo y solución para solución inyectable
Route: vía intramuscular
Register: Spain (AEMPS)
Status: Authorised
Status in the register: Autorizado, no comercializado
Authorised: 28 Jul 2011
Registration: 10614002
Marketing authorisation holder: Glaxosmithkline Vaccines S.R.L.
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica

Antigeno oligosacarido meningococo grupo a + Antigeno oligosacarido meningococo grupo c + Antigeno oligosacarido meningococo grupo w135 + Antigeno oligosacarido meningococo grupo y · 10 mg + 5 mg + 5 mg + 5 mg · polvo y solución para solución inyectable

Spain